Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MannKind Corp (NASDAQ:MNKD)

0.55
Delayed Data
As of Dec 02
 +0.0708 / +14.77%
Today’s Change
0.41
Today|||52-Week Range
2.24
-62.07%
Year-to-Date
MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions
Dec 01 / Zacks.com - Paid Partner Content
Penny Stocks: 2 to Buy, 2 to Avoid
Nov 20 / MotleyFool.com - Paid Partner Content
3 Biotech Investing Tips That Could Earn You Thousands
Nov 28 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close0.48
Today’s open0.50
Day’s range0.48 - 0.61
Volume9,055,324
Average volume (3 months)3,776,614
Market cap$263.1M
Dividend yield--
Data as of 3:59pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-78.43%
Earnings growth (this year)+112.45%
Earnings growth (next 5 years)+26.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

 Today’s
change
Today’s
% change
OCULOcular Therapeutix I...+0.25+2.71%
IDRAIdera Pharmaceutical...-0.03-1.86%
CMRXChimerix Inc-0.07-1.47%
ASMBAssembly Biosciences...+1.44+11.33%
Data as of 3:59pm ET, 12/02/2016

Financials

Next reporting dateMarch 20, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$0.00
Annual profit (last year)-$368.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
CEO, CFO, Director, VP &
Head-Investor Relations
Matthew J. Pfeffer
Chief Medical Officer &
Vice President
Raymond W. Urbanski
Corporate headquarters
Valencia, California

Forecasts


Search for Jobs